Three out of four pharmaceutical companies believe their industry is in the midst of a strategic crisis, new research finds. Pricing and cost pressures, regulatory changes and patent expiries are leading to shrinking margins, and the biggest growth opportunities are to be found in the emerging markets, albeit with smaller margins, says the report, from Roland Berger Strategy Consultants.
See on www.pharmatimes.com